Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update
Thomas H. Brannagan(Columbia University), Morie A. Gertz(Medical University of South Carolina), Peter D. Gorevic(Université Paris-Sud), John L. Berk(Boston University), Luca Gentile(University of Messina), Peter Aquino(Akebia Therapeutics (United States)), Annabel K. Wang(Université Paris-Sud), Violaine Planté‐Bordeneuve(Université Paris-Est Créteil), Carol Whelan(The Royal Free Hospital), Isabel Conceição(Université Paris-Sud), Arnt V. Kristen(Heidelberg University), Brian Drachman(Penn Presbyterian Medical Center), Laura Obici(University of Pavia), Kemi Olugemo(Akebia Therapeutics (United States)), Anna Mazzeo(University of Messina), Michael Polydefkis(Université Paris-Sud), Josep Maria Campistol Plana(Hospital Clínic de Barcelona), Josep Gámez(Université Paris-Sud), Giampaolo Merlini(University of Pavia), Teresa Coelho(Universidade do Porto), Merrill D. Benson(Indiana University School of Medicine), P. James B. Dyck(Mayo Clinic), Arvind Narayana(Teva Pharmaceuticals (United States))
Cited by 36
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k